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MICSO MICw 5 (96) MIC50 MICm S (%) 
Ccphdom 0.5 0.5 100 Ccfvolin 0.5 1 100 
C e 6 c 1 or 2 8 100 Cc@rozil 0.5 1 100 
Cefimndole 0.25 0.25 100 Cefumnmc 0.25 0.5 100 
Ccfaxitin 4 8 100 Cehinox 8 > 8 63 
Cefowime 0.25 0.5 100 Ceftriaxonc 0.25 0.5 100 
ccfrwdunc 4 8 96 C e f n m h c  0.5 1 100 
ccfuome 4 8 8 Ccfpodmmc 0.25 0.5 100 
Ceftibutcn > 16 > 16 0 Cefepime 0.5 1 100 
In general first and second generation cephalosporins presented 
good activity, although in the case of cefaclor and cefoxitin MICso 
were near the breakpoint and 37% of the strains were resistant to 
cefminox. Third generation cephalosporins of parented administra- 
tion and cefepime showed excellent activity, although MICso of cef- 
tazidune was near the breakpoint. In the group of oral third gener- 
ation cephalosporins, all the shains were susceptible to cefpodoxime 
but the majority resistant to cefixime and all to cefcibuten. 
Glycopeptides for enterococci and other 
Gram-positive cocci II 
[p7101 WanA Glycopeptide Resistant Enterococci: 
Identical vanA Gene Cluster in Glycopeptide 
Resistant Enterococci from Man and 
Avoparcin-Exposed Pouttry 
H. Haaheim, G.S. Simonsen, 0. Olsvik, H. Kruse, A. Sundsfjord. 
Dept. OfMedical Microbiolofl, N-9037 University of Tromsr, Noway 
Objectives: Identification and characterization of the genes encod- 
ing hgh-level glycopeptide resistance in enterococci h m  Norwe- 
gian and Swedish humans and avoparcin-exposed Norwegian poul- 
try. 
Methods: High-level glycopeptide resistant enterococci (GRE) 
isolated h m  feces of avoparcin-exposed Norwegian poultry (N = 
l l ) ,  dinical human GRE-isolates h m  Swedish (N = 4) and Nonve- 
gian (N = 1) patients, and fivm feces of Norwegian poultry farmers 
(N = 4) were idenhfied by phenotypical methods and species spe- 
nhc ddl-PCR. Van resistance genes were analysed by specfic w&-, 
vanA-, and a long PCR covering the earlier described vanA gene 
cluster, Tn1546. 
Results: All poultry GRE-isolates were identified as E. faen'um. 
Identification of the 9 human GRE-isolates revealed five E. faecium, 
three E. duram and one E. hirae. All 20 isolates scored positive and 
negative in the vanA and vanB specific PCR, respectively. The long 
PCR, covering 10.414-bp of the 10.851-bp Tn1546, scored positive 
in 619 human-GRE and 8/11 poultry-GRE. Restriction hgment 
analysis, HincII/BinI-digests, revealed identical patterns. 
Conclusions: The identical restriction fi-agment length patterns 
of vanA gene clusters in human and poultry GRE-isolates indi- 
cate but do not document horizontal vanA gene transfer between 
avopanin-exposed poultry GRE and human fecal enterococci. 
I P711 I Strains of E. faeciurn Can Alter Their 
Glycopeptide Resistance Genotype During an 
Outbreak 
D. Morrison', P. Chadwick', B.D. Cookson', N. Woodford'. 
'MI, CPHL, London, 'PHL, Manchester, UK 
During an outbreak of VanB enterococci on a Leukaemia unit, E. 
faecium was lsolated fivm two patients (isolates D and C, respectively). 
These isolates were identical to the outbreak strain by Pulsed Field 
Gel Electrophoresis (PFGE) of SmaI-digested DNA and ribotyping 
(rRNA probing of the PFGE gels). However, both D and C were re- 
sistant to t e i c o p h  (VanA phenotype). An isolate indstinguishable 
h m  the outbreak s t r a i n  had been recovered fivm patient D seven 
months previously. Three plasmid profiles were observed; isolate C 
and the outbreak strain carried plasmids with the wnA and the vanB 
genes, respectively, while D carried both the vanA and wnB genes 
on two Merent plasmids. mnB transconjugants were obtained h m  
D and the outbreak strain,  indcating transferable uanB resistance. 
The uanB plasmids in these isolates had identical patterns following 
EcoRV digestion and an identical firagment (2.1 kb) hybridised with 
a vanB probe. The plasmid profiles of D and C Mered only by the 
absence of this uanB phsmid h m  C. These data suggest that during 
the outbreak, the predominant strain of E. fwcium, carrying a uanB 
plasmid, acquired a v a d  plasmid and other mobilizable plasmids, 
and subsequently lost its vanB plasmid. T h  study W t s  the re- 
markable ability of E. 4ecium to acquire and lose resistance genes. 
Resistance genotyping must be used in conjunction with PFGE to 
define fully the epidemiology of glycopeptide-resistant enterococci. 
I P712 I Development of Resistance to Glycopeptide in 
S. Stefani, M.L. Mezzatesta, M. Puntorieri, M. Santagati, 
B. Incalcaterra, C. Azzarelli, G. Nicoletti. University of Catania, Italy 
Objectives: Great discussion is related to the origin of glycopep- 
tide resistance: the result obtained at both the DNA and protein 
levels are in favour of an exogenous origin for high-level glycopep- 
tide resistance in Enterococci, but results obtained by Dukta-Malen 
et al. showed no homology between the vanA probe and genomic 
DNA of s a a i n s  producing teicoplanin, neither to the gene present 
in intrinsically resistant strains. No informations are available regard- 
ing vanB origin. These situation contrast with the stepwise changes 
in susceptibility to vancomycin of S. haemolyticuc which suggest an 
indigenous origin, by chromosomal mutation, for glycopeptide resis- 
tance. The selective pressure of the use of glycopeptides is associated 
with the emergence of transferable glycopeptide resistance in ente- 
rococci, but no informations are published on the possible changtng 
in some phenotype and genotype characteristics. 
Methods: The possible development of resistance was studied by 
serd  transfer, performed as follows: five serial aansfer with subin- 
hibitory concentrations of vancomycin and teicoplanm were fol- 
lowed by five transfer in antibiotic h e  medium. These serial trans- 
fers were repeated for six cycles at concentrations half of the MICs 
obtained in any previous passage. Cross induction of resistance was 
determined. To avoid any contamination, identification of variants 
were verified by API Strepto System (Bio Merieux), and, when nec- 
essary, by using PFGE analysis. Stability of the acquired induction 
was assessed by MIC determination after five daily passages every 
cycle of variants in antibiotic h e  medum. 
Results: Our results show that no mutants resistant to glycopep- 
tides could be selected after induction experiments: however some 
strains showed increased MIC values (9 strains showed MIC of 8 
mg/l to vancomycin after induction with Mncomycin it& no 
strains showed intermediate values of t e i c o p h  &er t e icophn 
induction). Studies are in progress to confirm the possible changes 
related to glycopeptide pressure on enterococcal strains. 
Enterococci 
Glycopeptides for enterococci and other Gram-positive cocci II 171 
I P7 13 I In Vim Activity of LY 333328 Against 
Vancomycin Resistant (wad or vans 
Enterococci, Methicillin-Resistant S. aureus 
(MRSA), and Penicillin-Resistant Pneumococci 
(PRSp) 
K. Piper, M. Rouse, R. Patel, E Cocked, N. Henry, W. Wilson, 
J. Steckelberg. Mayo Clinic, Rochester, MN, USA 
The in vitro activity of LY 333328 (a nav glycopeptide) was 
compared with vancomycin against vancomycin-resistant entero- 
cocci (VRE), methich-resistant S. aureus (MRSA), and peni- 
cdin-resistant S. pneumoniae (PRSp). Vancomycin resistance geno- 
type was determined by PCR amplification with primers speclfic 
for vancornycin resistance genes mnA or vanB. VRE and MRSA 
MICs were determined in 2 mL total volume of cation supplemented 
MHB with an initial inocdum of lo5 cWmL of Iogarithrmcdy 
growing organisms pneumococcal MICs were determined in cation 
supplemented MHB plus 3% lysed horse blood in a total volume 
of 0.1 m~ with an initial inoculum of lo4 &/well of l o g a r i h -  
cdy  growing bacteria, as described by NCCLS document M7-A3. 
MBCs were determined by subculture of the MIC tests according to 
NCCLS document M26-T. The results of susceptibility testing are 
summarized as MIC90, MIC range, mC90 and MBC range. 
Organisms No. LY 333328 Vancomycin 
MlCgo MICRange MBCga MFKRange MIC90 MICRnnge 
m d V R E  9 2 0.5-2 8 2-8 >128 All> 128 
w n B V R E  1 1  0.5 <0.125-1 1 1-8 >I28 64->128 
MRSA 34 1.0 0.5-1.0 2.0 1 4  2.0 0.5-2 
PRSp 33 -&I25 AU <0.125 4 . 1 2 5  AU < 0.125 0.5 0.25-0.5 
All isolates tested were inhibited by 5 2  wg/mL of LY 333328 and 
lulled by 5 8  pg/mL. Further studies of the activity of LY 333328 
are warranted. 
[p7141 Activity of Teicoplanin and Vancomycin Against 
Staphylococcus and Enterococcus spp from 
Germany in 1995 
A. Bauernfeind. Max uon Pettenkofer Institute, Munich, Germany 
The in vitro activity of teicoplanin and vancomycin was determined, 
using standard agar dilution methodology, against 928 isolates of S. 
aurew (282), Coagulase Negative staphylococci (189) and Enterococcus 
spp (457), collected at nine hospitals in Germany in 1995. 
s. aurew 0.5 1 8 0.5 1 4 
S. rpidemridir 0.5 4 16 0.5 2 2 
Combined CNS 0.5 2 32 0.5 2 4 
E n t o w r r p p  0.25 0.5 64 1 2 64 
E.@eralir 0.25 0.5 1 1 2 32 
E. f m u m  0.5 64 64 1 64 64 
64 mg/L; vanA phenotype). One strain displayed intermediate resis- 
tance (MIC 8 mg/L) to vancomycin. 
FI Enhanced Activity of Teicoplanin over 
Vancomycin Against Streptococcus and 
Enterococcus spp 
L. Verbist for the Belgian Glycopeptide Resistance Group. ' UZ 
Sint-Rafael, Leuuen, Belgium 
As part of a European collaborative study, 719 consecutive 
Gram-positive isolates were collected at eight centres in Belgium in 
1995 and their susceptibhties (MICs) to teicoplanin and vancomycin 
determined using a standard agar dilution technique. Teicoplanin was 
at least four-fold more active than vancomycin against S. pneumoniae 
(n = 26) and other Streptococnrs spp (n = 86) with M I C ~ & I I C ~ O  
values of 50.125/1 and 10.125/<0.125 mg/L respectively. A single 
Group D Streptococcus h m  urine was resistant to teicoplanin and 
vancomycin (MIC 64 mg/L). Teicoplanin was also four-fold more 
active than vancomycin against E.faecalis (n = 158) with MICso and 
MICw values of 0.25 and 1 mg/L. No strains were resistant to van- 
comycin or teicoplanin. Only six isolates of Efaecium were collected 
of which one, a SSTI iso1ate;was resistant to both teicoplanin and 
vancomycin (VanA phenotype). Both antibiotics gave MIC5o values 
of 2 mg/L against S. epidermidis (n = 87) and 1 mg/L against S. 
aureus (n = 289). MIC90 values were two- and four- fold higher for 
teicoplanin. The six isolates of S. haemolyticus collected gave MIC 
ranges of 1-2 mg/L and 4 3 2  mg/l for vancomycin and teicoplanin, 
respectively. 
Ip7161 In Vim activity of Teicoplanin and 
Vancomycin Against Gram-Positive Isolates from 
France 
C.J. Soussy for the French Glycopeptide Resistance Group 
'Hopifal Henri Mondor, Creteil, France 
The susceptibhties of 815 consecutive Gram-positive isolates, col- 
lected at eight centres in France in 1995, to teicoplanin and van- 
comycin, were determined using a standard agar dilution technique 
as part of a European Collaborative study of glycopeptide resistance. 
Teicoplanin gave similar activity to vancomycin against S. aureus 
(MICC,~: 0.5 mg/L, n = 346) and coagulase negative staphylococci 
[CNS] (MIC50: 2 mg/L, n = 205), albeit with extended MIC ranges. 
Five (2.4%) s t r a i n s  of CNS were resistant to teicoplanin (MICs: 32 
mg/L). The majority of E .  faecium s t r a i n s  (n = 9) gave MICs of 
- (0.125 and 1 mg/L against teicoplanin and vancomycin respectively. 
However, one strain (VanA phenotype) required 64 mg/L of either 
agent for dubition. Teicoplanin was generally eight-fold more active 
than vancomycin against E .  faecalis (n = 78) with MIC90 of 50.125 
mg/L. One isolate of E. faecalis (VanB phenotype) was resistant to 
vancomycin alone (MIC 64 mg/L). Teicoplanin was highly active 
against Streptococcus spp (MIC50, 50.125 mg/L, MIC9o 0.25 mg/L, n 
= 124), particularly S. pneumoniae, whereas vancomycin was at least 
four-fold less active. 
~ ~~ ~ 
Teicoplanin and vancomycin were equipotent against S. aureus and 
CNS. However teicoplanin gave higher MICl0o S than vancomycin 
against S. epidermidis and S. haemolyticus. Teicoplanin was generally at 
least four-fold more active than vancomycin against Enterococcus spp. 
The majority 74.8%) of Enterococcus spp were E .  faecalis. One strain 
of E.  faecalis displayed intermedate resistance (MIC 8 mg/L) and 
another fd resistance MIC.32 mg/L) to vancomycin. 6/51 strains 
of E. faen'um (11.8%), including two h m  blood and four h m  skin 
infections were resistant to both teicoplanin and vancomycin (MIC: 
A Review of the Clinical and Bacteriological 
Efficacy of Teicoplanin Against Coagulase 
Negative Staphylococci 
R.N. Griineberg', I. Harding'. ' U C H ,  London, UK, '7'hackeZuy's 
Ltd, Deuizes, UK 
The clinical eacacy of teicoplanin against coagulase-negative staphy- 
lococcal (CNS) infections has been assessed in 16 comparative and 
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38 uncontrolled studies. The comparative studies involved a total of 
1558 patients with febrile neutropenia, bacteraemia, line infections 
or cancer. 310 patients had confirmed CNS mfecti0ns:- 
hnubiouc Studm Paoeno Pauenrr C h d  Bacrcnolqqc 
unthCNS response response 
Teicoplam 10 553 117 82.0% 84.3% 
Vulcomycm 533 112 93.0% 89.1% 
Tevophn 6 329 53 92.0% 92.096 
Other’ 143 28 71.4% 23.1% 
*Gcncanuciu/pipm*Uin, cciiandime, pipmdllin/uzobacram/ami!ucin. 
The 38 uncontrolled studies involved 658 patients with confirmed 
CNS infections. The chicallbacteriological responses in these stud- 
ies were: endocarditis (92%; loo%), FNEhne mfections (87%; 89%), 
bacteraemia 96% 96%), bone/joint (86%; 89%). skin and soft tissue 
(97%; 93%). and neonates/paediatrics (96%; 96%) with overall re- 
sponses (93%; 93%). 
Conclusions: Teicoplanin is as effective as other antibiotics in the 
treatment of CNS infections and has other advantages in terms of 
once dady administration, intramuscular use and improved tolerabil- 
ity. 
Efficacy of Teicoplanin in Infections Caused by S. 
aumus, Including Methicillin-Resistant Strains 
J.E. Degener 
Ltd, UK 
C h c a l  and bacteriological outcome data for infections caused by 
S. aureus h m  63 clinical hiah (46 uncontrolled and 17 controlled, 
inc. 11 vs vancomycin) were reviewed and analysed. In t o d ,  3161 
patients received teicoplanin in these studes;  2378 had infections 
caused by S. aureus, of which 1148 were MSSA, 422 MRSA, and 
808 undetermined isolates. Comparative evaluable clinical and bac- 
teriological responses are shown below: 
I. Hardmg’. ’ Groningen, Netherlands, 2Tharkehy’s 
Controlled srudxes: TeicopLnin Vvlcomycin 
No. (%) NO. (74) No. (%) No. (%) 
clinical success Bact. success Chid success Bzct. success 
MSSA 44 (65%) 71 (76.1%) 34 (73.5%) 62 (80.6%) 
MRSA 14 (85.7%) 21 (95.296) 12 (91. 7%) 21 (90.5%) 
s. aunw 94 (84.0%) 44 (77.3%) 100 (81.0%) 43 (76.7%) 
Tod 152 (78.W.) 136 (79.4%) 146 (80.1%) 126 (81.0%) 
CoamIM sh ld ia :  T c i c o p h  fi-kcum combllutlons 
No. (74) No. (??) No. (?A) No. (?A) 
Clinical succcss Ban. success Clinical success Baa. success 
MSSA 17 (88.2%) 120 (90.096) 10 (90.0%) 72 (86.1%) 
MRSA 0 (3 9 (66.7%) 0 (-) 4 (25.0??) 
s * u m  19 (94.7%) 19 (94.7%) 18 (83.3%) 18 (83.3%) 
Tod 36 (91.7%) 148 (89.2%) 28 (85.7%) 94 (83.0%) 
There were no sigruficant Herences between teicoplanin and 
comparators. In uncontrolled studes, clinical and bacteriological 
success rates were: MSSA 86.2% (n = 152 evaluable cases) & 83.0% 
(671); m S A  87.1% (116) & 85.7% (279); S. aureus 89.0% (499) 
& 87.5% (583). It is concluded that teicoplanin and vancomycin 
are equally effective against S. aureus, includmg methdlin-resistant 
strains. 
I P719 I An Analysis of Pathogen Susceptibility, Dosage 
and Sewn Levels versus Clinical Outcome in 
Infections Treated with Teicoplanin 
A.P.R. Wilson’, I. Hardmg’. ‘UCH, London, UK, ’Thadeelay’s 
Lid, Devires, UK 
Susceptibility data and c h c a l  outcome in 3 defined types of in- 
fection treated with teicoplanin (vascular-access bacteremia P A C T ,  
bone and joint infection PJ and skin/soft tissue infection [SST) 
were analysed to determine the relationship between dose, serum 
level, MIC and outcome. In total, data h m  459 patients were avail- 
able for analysis (47 BACT, 149 BJ and 263 S S T ) .  All patients re- 
ceived teicoplanin at doses ranging h m  3 to 12 mg/kg. In BACT, 
43 of 47 (91.5%) patients were cured; trough serum levels exceeded 
MIC by a factor of 4 in most cases. The major pathogens were S. 
aureus and S. epidmidis; in 3 cases caused by S. hemolyticus, with 
MICs of 2 (n = 1) and 16 mg/L (n = 2), the outcomes were two 
cures and one failure (MIC 16 mg/L). In BJ, there was no sigdicant 
relationship between MIC and outcome. Treatment failed in 3/25 
chronic osteomyelitis and 1/29 acute osteomyelitis caused by S. (IU- 
reus (MIC range 0.25-2, median trough level 15 mg/L) suggesting 
that underlying factors were more predictive than pharmacodynam- 
ics. Similarly, in SST, there was no significant relationshp between 
dosage, serum level or MIC of the infecting pathogen and &cal 
outcome. However, higher doses of teicoplanin ( 6 1 0  mg/kg) were 
more successful in lnfections with mixed aetiology (45/59, 76% vs 
50/52,96%). In general, whilst there was a suggestion ofhigher cure 
rates in infections caused by more sensitive pathogens, other factors 
such as extent of vascularisation or use of combination therapy may 
be more of greater importance. 
I P720 I MetaAnaIysis of Teicoplanin Safety Data 
D. Vogelaers I ,  I. Harding ’. ’ University Hospital Gent, Belgium, 
2Tlurckelay’s Ltd, Dwizes, UK 
Early preparations of vancomycin were associated with a high inci- 
dence of AEs, which have been sigdicantly reduced by improved 
purification. Teicoplanin has a similar structure to vancomycin, but 
a longer half life, inttavenous and intramuscular formulations, and 
reduced nephmtoxicity in combination with aminoglycosides. The 
most common AEs in a series of 3377 patients were hypersensitivity 
(2.6%), abnormal liver function (1.7%), fever (0.8%). local intoler- 
ance (1.6%), abnormal renal function (0.6%) and ot&city (0.3%). 
Of 6696 patients on file, 3.1% experienced rash, 2% fever, 1% rig- 
ors, 1% diarrhoea and 1% nausea. Comparative trials of teicoplanin 
and vancomycin in the USA (825 patients) showed similar incidence 
of AEs for the two agents. In 14 comparative trials, there were 
40/965 (4.1%) instances of nephmtoxicity among patients receiving 
teicoplanin at 6 mg/kg/day plus an aminoglycoside compared to 
75/951 (7.9%) patients receiving vancomycin plus aminoglycoside. 
Red-man syndrome is observed in up to 47% patients following 
rapid infusion of the fint dose of vancomycin and can be avoided 
by slow infusion rates of 30-60 min. The syndrome, which may 
be due to histamine release, also occurs with highly purified van- 
comydn, suggesting the molecule rather than impurities are respon- 
sible. Only 3/6696 (0.04%) patients receiving teicoplanin have expe- 
rienced red-man symptoms. Fever and rash normally occur at 2-3% 
with teicoplanin but can occur at up to 28% following prolonged 
treatment. Neutropenia is tare at normal dosages (0.0743%) but the 
incidence can rise in patients receiving very high doses. Teicoplanin 
is not associated with severe liver toxicity or gastro-intestinal AEs. 
Conclusion: Within the class of glycopeptides, teicoplanin has a 
favourable safety profile, allowing bolus adrmnistration and reducing 
the requirement for routine serum monitoring. 
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1 P721 I Comparative Serum Concentrations of 
Teicoplanin and Vancomycin 
L. Verbist I ,  I. Harding *. UZ Sint-Rafael, Leuuen, Belgium, 
’ntnckelay’s Ltd, Deuizes, UK 
Comparative serum concentration data from 3 clinical trials of te- 
icoplanin (T) vs vancomycin (V) have been reviewed. In total, 255 
patients were available for data analysis: 123 T and 132 V. Groups 
were well-matched for age, sex and weight. Infections treated in- 
cluded FNE, line dections and septicemia. There was no diEerence 
between treatment groups in terms of &cal (T, 83.5% success; V, 
82% success) or bacteriological response p. 81% eradtcation; V, 87% 
eradication). Mean dady doses were: T, 380 mg/5.8 mg/kg (range 
124-1080 mg) and V, 1888 mg/29.1 mg/kg (750-3125 mg). Most 
patients received monotherapy or combination therapy with two 
other antibacterials, including aminoglycosides, and c. 15% received 
aminoglycosides prior to glycopeptide theram. Estimated creatinine 
clearance values (CrCl) were lower in T patients at baseline (102 
vs 115 mL/min) but changed signlficantly more during treatment 
with vancomycin (-6.6, -6.5% change vs -23.1, -20.1% change; 
p < 0.05). Mean trough serum levels, by dose for T, were: <5 
mg/kg/day, 6.8 f 4.8 m g k ,  5-7.5 mg/kg/day, 9.3 f 5.9 mg/L. 
Mean trough levels for V were 11.9 f 7.7 mg/L. Levels for both 
glycopeptides were hgher during days 4-7 of treatment than during 
days 1-3. High mean through levels were achieved in elderly patients 
(>65, n = 44) with V (15.9 mg/L) but not T (6.2 mg/L). These re- 
sults confirm the comparable efficacy of T and V, that through levels 
can be variable for both glycopeptides but are close to target ranges, 
and that V is associated with more decreases in renal function, as 
measured by CrCl, than T. 
[=I Comparative Efficacy and Safety of Teicoplanin 
and Vancomycin 
. R.C. Spencer ’, I. Harding’. ‘PHLS, Brisfol, UK, Z7’hackelay’s Ltd, 
Devizes, UK 
Fifteen clinical trials involving 1526 patients have been reviewed to 
compare the efficacy and safety of teicoplanin (T) and vancomycin 
0. 
Refercncc Eduable CbUCd Bact Response 
T V T V T  V 
Gerard, 1987 
Van Lcthcm. 1988 
Smth, 1989 
Kulmali, 1990 
Cony-Makhoul, 1990 
Kurcrh. 1991 
Van der Auwcn, 1991 
Choi, 1992 
Gdhert. 1991 
Charbonncau, 1994 
Memchetu. 1994 
Hedsuom. 1994 
Nevlllc, 1995 
Studem. 1995 
hguen, 1996 
21 19 72 82 
35 37 66 71 
118 122 88 89 
24 35 54 60 
26 27 92 84 
37 37 75 74 
22 20 77 70 
22 25 71 94 
24 32 80 83 
275 252 78 75 
53 27 87 93 
26 28 76 68 
21 21 81 81 
68 58 68 55 
12 9 92 9o 
81 84 
92 90 
71 75 
84 86 
not cdculablc 
92 100 
78 66 
71 94 
81 84 
92 87 
88 88 
71 78 
no information 
35 54 
not cdculiblc 
Analysis of the combined results indicated that more than three 
quarters of the patients in each of the treatment groups had a success- 
ful c h c a l  and bacteriological response to therapy, with no Merence 
between treatment groups. There were markedly fewer reports of 
adverse events in patients receiving teicoplanin (14%) than in those 
receiving vancomycin (22%). 
I P723 I Comparative In-Vita Activities of Vancomycin 
and Teicoplanin Against Gram-Positive Cocci in 
a Turkish Teaching Hospital 
L. Miiladmo&~, E Dilmen, G. Soyletir, V. Korten. Marmara 
University School of Medicine, Istanbul, Turkey 
The in-vim, activity of teicoplanin was evaluated comparatively to 
vancomycin against 121 gram-positive cocci just before the mar- 
keting of teicoplanin in Turkey The isolates include 26 coagulase 
negative staphylococci recently obtained h m  patients with vari- 
ous prosthetic device dections. In vim susceptibility tests were 
pedormed by agar dilution and &sk difhsion methods following 
NCCLS guidelines. The results are shown in the table: 
Orgvliun (No)  Teicoplanin (pg/ml) Vmcomycin (pg/ml) 
Range MIC50/90 Range MIC50/90 
MRSA (30) 0.2- OW2 0.5-2 112 
Coagg(-) staph. (26) 0.254 0.5/1 1-2 212 
Entcrococd (28) 0.25-4 0.2Y0.25 0.5-4 1/2 
S. pncumontar (20) 0.03-0.06 0.03/0.06 0.061 0.25/0.5 
Viridamscp. (17) 0.03406 0.03/0.06 0.2H.5 0.2V0.5 
On the basis of MlCs for 50% of the strains tested, teicoplanin was 
2-8 fold more active against all gram-positive cocci as compared to 
vancomycin. There was a good correlation between two susceptibil- 
ity methods except two intermediately teicoplanin susceptible isolates 
with disk method being M y  susceptible with agar dilution. There was 
no t e i c o p h  resistant isolate before the marketing of the drug. 
I P724 I The Effect of Vancomycin on the Intestinal Flora 
of Patients Previously Receiving Antimicrobial 
Therapy 
C. Edlund I ,  L. Barkholt I ,  B. Olsson-Liljequist ’, C.E. Nord I .  
’Dq .  $Immunology, Miuobiology, Pathology and Infem’ous Diseases, 
Karolinska Institute, Stockholm, Sweden, ’Swedish Institutefor lnfecrious 
Disease Control, Stockholm, Sweden 
Objectives: To determine whether the use of oral vancomycin is 
associated with an increased fkquency of vancomycin-resistant rn -  
croorganisms, and to determine faecal concentrations of vancomycin 
and correlate the levels with quantitative and quahtative alterations 
of the intestinal microflora. 
Methods: Twenty healthy volunteers received cefuroxime axed 
tablets (250 mg) perorally b id .  for 1 week, and 10 of these received 
subsequently vancomycin capsules (125 mg) perorally q.i.d. for 7 
days. Faecal samples were collected h m  all subject on days 0, 7, 10, 
14,21, and 28. 
Results: The concentration of vancomycin in feces after 1 week 
vancomycin administration was high (mean (SD) 520 (197) mg/kg), 
which correlated with the ecological disturbances noted in the van- 
comycin group. Vancomycin adminutration resulted in a rapid de- 
crease of intestinal Enterococcus faecium, Enterococcus faecalis and En- 
terococcw durans ( P  5 0.05), and a selection of motile enterococci 
with decreased susceptibility to vancomycin (Enferocoms gallinarum 
and Enferococrus rassilfiuus, MIC 4-16 mg/L) (P 5 0.01). There was 
also a significant overgrowth of vancomycin resistant Pediococcus sp. 
and lactobacilli, as well as of Mebsiella sp., Citrobacter sp. and Enter- 
obacter sp. ( P  5 0.01), while bifidobacteria and Bacteroides sp. were 
sigdicantly reduced in numbers during vancomycin administration. 
All motile enterococci carried the w n C  gene, whde none of these 
strains carried uanA or uanB gene. 
Conclusions: Administration of vancomycin sigdcantly selects 
for intestinal gram-positive bacteria with decreased susceptibility to 
vancomicin. 
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Successful Treatment of Vancomycin-Resistant 
Enterococcal (VRE) Infections with Teicoplanin 
I. Warding. Thackelay's Ltd,  Devizes, UK 
During a compassionate program in the USA, 12 patients were 
treated with te icophn for infections caused by W. Infections 
(mean duration 31d) treated included sepsis (6), abdominal abscess 
(3), endocarditis, wound infection and mfected ulcer (1 each). Pa- 
tients had mean age 49.3 y (range 20-82) and multiple underlying 
conditions including organ transplants, leukemia and renal/hepatic 
failure. All had received previous antibacterial therapy with one or 
more agents (vancomycin in 8 cases)., and all received concomi- 
tant antibacterials with teicoplanin (usually aminoglycosides). Te- 
icoplanin was given on a mg/kg basis, following a loadmg dose, 
with dady doses ranging from 200 to 1450 mg. Mean duration of 
treatment was 36d (range 7-89). Pathogens included Efaecium Q, 
Enferococcus spp. (3), E. duram and E. cacsellpaous (1 each). All were 
resistant to vancomycin (MIC range 16256 mg/L) and susceptible 
to teicoplanin, showing vanB and vanC phenotypes. Four patients 
had mixed mfections; the patient with resistant E. durans also had 
a vancomycin-susceptible E. faecium. Pathogens were grown finm 
blood culture in 8 cases and tissue specimens in the remainder. Nine 
patients were cured, one improved and two faded treatment with 
teicoplanin. Pathogens were eradicated in 10 patients; one experi- 
enced persistence of an Entemwms spp. from an abdominal abscess, 
and both E. duram (vancomycin-resistant) and E. faecium (suscepti- 
ble) persisted in another patient with sepsis. This patient died sub- 
sequently and was found to have endocarditis on autopsy. Only one 
patient experienced a teicoplanin-related AE (rash). It is concluded 
that t e i c o p h  is effective and safe in the treatment of infections 
caused by VRE. 
I P726 I Minimum Inhibitory Concentrations of 
R. Auckenthaler for the Swiss Glycopeptide Resistance Group. 
Hopital Universitaire de Genwe, Switznland 
In 1995, 826 consecutive Gram-positive isolates were collected at 
eight centres in Switzerland and their susceptibilities to teicoplanin 
and vancomycin determined using standard agar dilution method- 
ology. Teicoplanin was particularly active against Streptococcus spp (n 
mg/L compared to an MIC9o of 0.5 mg/L for vancomycin. Simi- 
larly, teicoplanin (MIGO: 0.5 mg/L) was eight fold more active than 
vancomycin against Enterococcus spp (n = 141). Two of the twelve 
strains of E. faecium collected displayed the vanA phenotype and 
were resistant (MIC 64 mg/L) to both teicoplanin and vancomycin. 
A further two strains of E. faecium displayed intermediate resistance 
to vancomycin (MIC 8 mg/L; vanEI phenotype). Against staphylo- 
cocci, teicoplanin was two fold more active than vancomycin against 
S. aureus (n = 303) with an of 1 mg/L but nw fold less ac- 
tive against coagulase negative species (n = 122) with an M Q O  of 4 
mg/L. For all staphylococci, teicoplanin exhlbited an extended MIC 
range with a maximum value of 16 mg/L. Among other species col- 
lected only one strain, a Pediococncc sp., was resistant to teicoplanin 
and vancomycin. 
Teicoplanin and Vancomycin in Switzerland 
= 141) with an MIC90 of 50.125 mg/L and an MIClm of 0.5 
A 1995 Survey of Teicoplanin and Vancomycin 
Activity Against 907 Gram*-positive Bacteria in 
Spain 
E Baquero. Hopital Ramon y Cajal, Madrid, Spain 
The agar dution MICs of teicoplanin and vancomycin were deter- 
mined against 907 consecutive Gram-positive bacteria collected at 
nine centres in Spain in 1995. Teicophn exhibited superior ac- 
tivity to vancomycin awnst all bacterial species tested, except S. 
haemolyticuirus, and was particularly potent against Strrptococcus and En- 
terococcus spp. 
Taxa N Teicophin Vancomyan 
MIC50 MICW MIC5O MICw 
S. n u m  
Coag Neg. Staph 
- S. epidmnidir 
- S. hmme@imr 
shrprmolrur spp 
- S. pncumonim 
Enfmvwus spp 
- E. foeca1u 
- E. Jmaum 
294 
200 
134 
11 
135 
71 
m 
198 
12 
0.5 
0.5 
2 
5 0.125 
5 0.125 
5 0.125 
5 0.125 
5 0.125 
0.25 
0.5 
2 
2 
8 
5 0.125 
5 0.125 
0.5 
0.5 
0.25 
1 
1 
1 
1 
0.125 
0.125 
1 
1 
0.5 
2 
2 
2 
1 
0.25 
0.25 
2 
2 
2 
Eight strains of E. faeralis (4.04%) isolated finm blood, urine, skin 
and gastm-intestinal infections were resistant (MIC 64 mg/L) to both 
te icophn and vancomycin, ie VanA phenotype. No resistant strains 
were found among the other species tested. 
I P728 I Susceptibility of Principal Gram-Positive 
Pathogens in Portugal to Teicoplanin and 
Vancomycin 
J. Melo-Cristino for the Portuguese Glycopeptide Resistance 
Group. 'Institute Camara Pestana, Lisbon, Portugal 
A total of 522 consecutive Gram-positive strains were collected at 
five centres in Portugal in 1995 as part of a European survey of resis- 
tance to glycopeptides. MIC results (agar dilution) for the principal 
taxa were:- 
Vancomymn TUU N Teicophmn 
MICSO MICw MICso MIC90 
s. *"MI 
Coag Neg. Staph 
- S. cpidmnidzr 
- s. hmolytirur 
Strcptocwur spp 
- S. pncumonide 
Enmmcomrr spp 
- E.lneulk 
- E. Jaaium 
1 87 1 4 
166 2 8 
124 2 8 
21 2 8 
36 5 0.125 
11 5 0.125 5 0.125 
128 0.25 1 
89 0.25 1 
29 0.5 32 
0.5 
1 2 
2 2 
2 2 
1 2 
0.25 1 
0.25 0.25 
1 4 
1 4 
1 64 
Teicoplanin exhibited superior activity against Streptococcus and En- 
terocorcus spp. The agents were equipotent against s. aureus. Van- 
comycin was more active against coagulase negative staphylococci. 
Four blood isolates of S. epidennidis (3.2%) and two isolates (one 
blood, one urine) of S. haemolyticus (9.5%) displayed intermediate 
resistance to t e i c o p b  (MIC 16 mg/L). Four isolates (2 blood, 1 
urine, 1 skin) of E.faecium (13.8%) were resistant to both t e i c o p h  
and vancomycin (vanA phenotype). 
1 P729 1 Activity of Teicoplanin and Vancomycin Against 
E.A. Debbia for the Italian Glycopeptide Resistance Group. 
'Istifuto di Mimbiologia, Genova, Italy 
1002 Gram-positive isolates were collected at 10 Italian centres, as 
part of a 1995 European Glycopeptide Resistance Survey. Suscep- 
tibihties (MICs) to teicoplanin and vancomycin were determined 
using agar dilution. 
Staphylococci, Streptococci and Enterococci 
Epidemiology of antibiotic resistance II 175 
Epidemiology of antibiotic resistance II 
Spectcs N MIC (mg/L) rrqurrd to mhblt  % S ~ N  
~ ~~ 
Telcophnm vvlcomycln 
50% 90% 100% 50% 90% 100% 
S aweus 
111 Coag -ve Staph 
S eprdmnidlr 
S hacmolyhrur 
E n t o r o m  spp 
E >eraits 
E >mum 
strrptocom Ipp 
428 
191 
124 
29 
34 
323 
208 
47 
1 
2 
2 
2 
5 0.125 
0.25 
0.25 
0.5 
4 8 1 2  4 
8 1 6 2 2  4 
8 1 6 2 2  4 
8 1 6 2 2  4 
1 4 1 2  4 
1 6 4 2 4 6 4  
0.5 64 2 4 64 
2 64 1 2 64 
On the basis of MIC90 criteria, vancomycin was 2-4 times more 
active than teicoplanin against staphylococci whereas teicoplanin was 
at least two fold more active against streptococci. Teicoplanin was 
generally four to eight fold more active than vancomycin against the 
majority of Enterococcus spp. The incidence of enterococci resistant 
to teicoplanin (0.62%) and vancomycin (0.93%) was low. 
F1 Activity of Teicoplanin, Vancomycin and 8 Other 
Drugs Against Gram-Positive Pathogens Isolated 
in Italy 
G.C. Schito, A. Pesce, A. Marchese, E.A. Debbia for the Italian 
Glycopeptide Resistance Group. Institute tfMicrobiobBy, School .f 
Medicine, University .f Genoa, Italy 
At present only the glycopeptides teicoplanin and vancomycin re- 
tain, in most sites, a consistent activity against multi-drug resistant 
Gram-positive pathogens responsible for serious infections in the 
community and in n o s o c o d  settings. Thus, monitoring their con- 
tinuous efficacy becomes essential since the clinicians are accustomed 
to use these drugs on an empirical basis. In 1995 a large multicenter 
study enrolling 70 laboratories in 9 European countries has analysed 
6824 Gram-positive isolates for susceptibility to the two glycopep- 
tides. In Italy, besides teicoplanin and vancomycin, the in vifro ac- 
tivity of several other relevant drugs was assessed by an agar dilution 
method (NCCLS) on the collection of strains (807) sent to this coor- 
ha t ing  laboratory. Percent susceptible organisms at the breakpoints 
(NCCLS, 1995) are reported in the table for the antibiotics tested 
Pathogen X Surccpnble orguusms to 
n amp pen cef 1m net ery nor cip CCL vul 
Staph. (MS) 280 32.5 100 1W 95 51 75 69 100 100 
Staph. (MR) 219 80 10 14 10 99.6 100 
E. faemfu 247 87 94 66 42 99.6 99.6 
E. fam'um 46 28 43 52 17 100 98 
Thts  SUN^ confirms that teicoplanin is more active than van- 
comycin on Enterococci and that it displays in practice comparable 
potency against the Staphylococci. In accordance with the data ob- 
tained in other countries it may be concluded that usage of the two 
glycopeptides, as occurring in Europe, may delay the appearance and 
spread of glycopeptide-resistant Gram-positive pathogens as experi- 
enced in other regions of the world where only one molecule is 
employed. One possible mechanism for this may be ascribed to the 
fact that vancomycin can easily induce organisms carrying the VanB 
phenotype to f d  blown resistance while teicoplanin is devoid of this 
untoward effect. 
[p7311 Emergence of Fluoroquinolone Resistance in 
M. Kresken, D. Hafher for the Study Group. Paul-Ehrlich-Son'etyfor 
Chemotherapy, Study Group 'Bacterial Resistance', Cologne, &any 
Objectives: To evaluate the influence of an increasing consumption 
of fluoroquinolones on the prevalence of fluoroquinolone resistance 
in chical isolates of fiequently encountered bacterial species. 
Methods: The susceptibility data b m  4 collaborative Studies 
(each comprising more than 20 centres) conducted in 1983 (prior to 
the introduction of any fluoroquinolone), 1986 (after introduction 
of norfloxacin and ofloxacin in Germany), 1990 (after introduction 
of ciprofloxacin in Germany), and 1995 were analyzed. Uniform 
standard methods for idenbfication of the bacteria and susceptibility 
testing were used. MICs were determined by the broth microdi- 
lution method. A total of 14,960 strains were under investigation. 
Data are presented for ciprofloxacin regarded as a representative flu- 
oroquinolone. 
Results: Considering 2 4  mg/l as a breakpoint for resistance to 
ciprofloxacin the incidence of resistant s t r a i n s  of Enterobacterimeae 
remained below 1% until 1990, but increased to 3.8% (E. coli 5.2%) 
in 1995. The resistance rates in I! aeruginosa were 0.7%. 1%, 6.4%, 
and 11.9%, in S. aureus 0%. 0.5%, 6.2%, and 12.8%, and in E.faecalis 
2.2%, 0.7%, 7.7%, and 28.9%. The resistance rate in CNS increased 
b m  19.6% (1990) to 44.5% (1995). In the latest study E .  faen'um, 
M R S A ,  and M R - C N S  had the highest resistance rates (73.1%, 89.6% 
and 69.8%, respectively). 
Conclusions: The increasing consumption of fluoroqinolones 
seems to select resistant populations. Fluoroquinolone resistance has 
emerged in Central Europe. 
Central Europe 
Multicenter Survey of Eschenchia coli Resistant 
to Ciprofloxacin: Analysis of Clonal Diversity 
and Gyrase Mutation 
C. Nonhoff:', M. Delm&e*, MJ Struelens' for the Multicenter 
Study Group. 'Laboratoire de Microbiologie, HGpital Erasme, UniversitC 
Libre de Bruxelles, Belgium, Unid  de Microbiologie, HGpital St. LAC, 
Universid Cathofique de Louvain, Brussels, Belgium 
Objectives: To determine the rate of ciprofloxacin (CIP) resistance 
by using the ATI3 system in E .  coli isolates collected from two mul- 
ticenter surveys of l l Belgian hospitals and to define clonal diversity 
and gyrase mutation in CIP-E. coli isolates. 
Methods: CIP-R isolates were analysed by genomic typing (Ar- 
biuary Primer-PCR analysis using ERIClR and ERIC2 primers 
and PFGE analysis using XbaI). Detection of gyrA codon 83 mu- 
tation was done by using PCR amplification of the gyrA QRDR 
region and H i n j  RFLP analysis. 
Results: The rate of CIP-R in E. coli isolates increased from 
121520 (2%) in 1991 to 27/504 (5%) in 1993 (p -= 0.01). CIP 
MICs ranged &om 4 to 64 wg/ml. AP-PCR analysis discriminated 
14 genotypes and PFGE typing delineated 15 major types among 
23 a d b l e  CIP-R isolates fiom 1993 survey. Genotypes appeared 
geographically dispersed. All CIP-R isolates exhibited the most fie- 
quently reported mutation in codon 83 ofByrA. 
Conclusions: These data indicate that CIP resistance is increas- 
ing among'E. coli isolates b m  hospitalized patients in Belgium. 
Genomic diversity suggests that polyclonal emergence of CIP-R 
mutants is the predominant mechanism. Although a common ByrA 
mutation was found in CIP-R strains, the presence of additional 
mutations in gyrA and/or p a C  genes may explain the high resistance 
displayed by the majority of strains. 
